Fundamental Analysis of BRASKEM SA-CLASS A- ADR(NYSE:BAK) stock

Fundamental Rating

BAK gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 83 industry peers in the Chemicals industry. Both the profitability and financial health of BAK have multiple concerns. BAK is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

BAK had negative earnings in the past year.

In the past year BAK has reported a negative cash flow from operations.

BAK had negative earnings in 4 of the past 5 years.

Of the past 5 years BAK 4 years had a positive operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -5.12%, BAK is doing worse than 80.72% of the companies in the same industry.

BAK has a worse Return On Equity (-93.87%) than 91.57% of its industry peers.

		Industry Rank	Sector Rank
ROA	-5.12%
ROE	-93.87%
ROIC	N/A

ROA(3y)2.32%

ROA(5y)1.54%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

In the last couple of years the Operating Margin of BAK has declined.

Looking at the Gross Margin, with a value of 2.66%, BAK is doing worse than 90.36% of the companies in the same industry.

In the last couple of years the Gross Margin of BAK has declined.

The Profit Margin and Operating Margin are not available for BAK so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	2.66%

OM growth 3Y-5.67%

OM growth 5Y-20.61%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-2.5%

GM growth 5Y-14.73%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BAK does not have a ROIC to compare to the WACC, probably because it is not profitable.

BAK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of 0.96, we must say that BAK is in the distress zone and has some risk of bankruptcy.

BAK has a Altman-Z score of 0.96. This is in the lower half of the industry: BAK underperforms 78.31% of its industry peers.

BAK has a Debt/Equity ratio of 10.77. This is a high value indicating a heavy dependency on external financing.

The Debt to Equity ratio of BAK (10.77) is worse than 96.39% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	10.77
Debt/FCF	N/A
Altman-Z	0.96

ROIC/WACCN/A

WACC8.34%

2.3 Liquidity

BAK has a Current Ratio of 1.54. This is a normal value and indicates that BAK is financially healthy and should not expect problems in meeting its short term obligations.

With a Current ratio value of 1.54, BAK is not doing good in the industry: 72.29% of the companies in the same industry are doing better.

BAK has a Quick Ratio of 1.03. This is a normal value and indicates that BAK is financially healthy and should not expect problems in meeting its short term obligations.

The Quick ratio of BAK (1.03) is worse than 67.47% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.54
Quick Ratio	1.03

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for BAK have decreased strongly by -61.19% in the last year.

EPS 1Y (TTM)-61.19%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-414.61%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-7.85%

3.2 Future

The Earnings Per Share is expected to grow by 38.92% on average over the next years. This is a very strong growth

Based on estimates for the next years, BAK will show a small growth in Revenue. The Revenue will grow by 6.65% on average per year.

EPS Next Y33.12%

EPS Next 2Y41.16%

EPS Next 3Y38.92%

EPS Next 5YN/A

Revenue Next Year7.98%

Revenue Next 2Y8.48%

Revenue Next 3Y6.65%

Revenue Next 5YN/A

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

BAK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year BAK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

BAK's Enterprise Value to EBITDA is on the same level as the industry average.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	15.79

4.3 Compensation for Growth

BAK's earnings are expected to grow with 38.92% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y41.16%

EPS Next 3Y38.92%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

BAK does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BRASKEM SA-CLASS A- ADR

NYSE:BAK (7/26/2024, 7:18:07 PM)

After market: 6.44 0 (0%)

6.44

+0.12 (+1.9%)

Chartmill FA Rating

GICS SectorMaterials

GICS IndustryGroupMaterials

GICS IndustryChemicals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap2.57B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-5.12%
ROE	-93.87%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	2.66%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.79

Health

		Industry Rank	Sector Rank
Debt/Equity	10.77
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	1.54
Quick Ratio	1.03
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-61.19%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y33.12%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

BRASKEM SA-CLASS A- ADR (BAK)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens